A Phase II Trial of Aprinocarsen, an Antisense Oligonucleotide Inhibitor of Protein Kinase C α, Administered as a 21-Day Infusion to Patients with Advanced Ovarian Carcinoma

Cancer

Volumn 100, Issue 2, 2004, Pages 321-326

  Advani, Ranjana ^a   Peethambaram, Prema ^b   Luto, Bert L ^a   Fisher, George A ^a   Hartmann, Lynn ^b   Long, Harry J ^b   Halsey, Joanne ^a   Holmlund, Jon T ^c   Dorr, Andrew ^c   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Ovarian neoplasms; Phase II clinical trials; Protein kinase C

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; CA 125 ANTIGEN; ISIS 3521; PLATINUM; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENDOCARDITIS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RIGOR; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING; XENOGRAFT;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; QUALITY OF LIFE; SELF ASSESSMENT (PSYCHOLOGY); THIONUCLEOTIDES;

EID: 9144226837     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11909     Document Type: Article

References (11)

1. Basu A. The potential of protein kinase C as a target for anti cancer treatment. Pharmacol Ther. 1993;59:257-280.
2. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994;13:411-431.
3. Henry S, Montheith D, Bennett F, Levin A. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C raf kinase. Anticancer Drug Design. 1997;12:409-420.
4. Dean NM, McKay R. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligonucleotides. Proc Natl Acad Sci USA. 1994;91:11762-11766.
5. Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol Pharmacol. 1996;50:236-242.
6. Yuen A, Halsey J, Fisher GA, et al. Phase I study of an anti sense oligonucleotide to protein kinase C-a (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res. 1999;5:3357-3363.
7. Crooke ST, Bennett CF. Progress in anti sense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107-129.
8. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001;19:1809-1817.
9. Fleming T. One-sample multiple testing procedures for Phase II clinical trials. Biometrics. 1982;38:143-153.
10. Glantz SA. Primer of biostatistics, 2nd ed. New York: McGraw-Hill, 1987:317-325.
11. Isonishi S, Ohkawa K, Tanaka T, Howell SB. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer. 2000;82:34-38.